人外周型苯二氮卓受体及其突变受体cDNA克隆和序列分析

用ＲＴ－ＰＣＲ方法扩增并克隆了三种人外周型苯二氮卓受体ＰＢＲｃＤＮＡ,测序表明,４４２ｂｐ片段与献报道相比缺失８４ｂｐ编码序列,其转录水平高于正常ＰＢＲ,该序列编码一个与ＰＢＲ结构相关但缺失了２８个氨基酸残基的突变受体蛋白,这一异常转录本可能是通过选择性剪接方式转录产生并只存在于中国人肝癌ＢＥＬ７４０２细胞系,表明ＰＢＲ基因表达具有细胞特异和异质性,突变受体的发现为研究ＰＢＲ的结构和功能提供了理     

人外周型苯二氮卓受体及其突变受体cDNA克隆和序列分析

用ＲＴ－ＰＣＲ方法扩增并克隆了三种人外周型苯二氮卓受体ＰＢＲｃＤＮＡ,测序表明,４４２ｂｐ片段与文献报道相比缺失８４ｂｐ编码序列,其转录水平高于正常ＰＢＲ．该序列编码一个与ＰＢＲ结构相关但缺失了２８个氨基酸残基的突变受体蛋白．这一异常转录本可能是通过选择性剪接方式转录产生并只存在于中国人肝癌ＢＥＬ７４０２细胞系,表明ＰＢＲ基因表达具有细胞特异性和异质性．突变受体的发现为研究ＰＢＲ的结构和功能提供了理想的分子和细胞模型     

中枢型苯二氮受体研究

一、选题的由来苯二氮(艹卓)类(benzodiazepines,BZs)药物的研究始于50年代中期。由于其安全指数大、副作用小,现已成为处方频率最高的药物之一。据Tallman等的报道,美国10%的处方使用了该类药物,全年销售量高达8 000吨。自第一个BZs药物利眠宁于1960年用于     

外周苯二氮(艹卓)受体激动剂Ro5-4864抑制大鼠心肌细胞线粒体通透性转换

线粒体通透性转换（mitochondrial permeability transition,MPT）导致线粒体氧化应激性损伤。近年研究认为,位于线粒体外膜的外周苯二氮节受体（peripheral benzodiazepine receptor,PBR）参与了线粒体的重要生理功能。本研究在心肌细胞线粒体水平探讨激动PBR能否抑制Ca^2＋诱发的MPT。分离Sprague—Dawley大鼠心肌细胞线粒体,将PBR激动剂Ro5-4864（50、100、200μmol／L）和线粒体孵育,利用150μmol／L Ca^2＋诱发MPT,部分线粒体在与100μmol／L Ro5-4864孵育前5min加入MPT孔道开放剂苍术苷（atractyloside,ATR）。采用分光光度法观察线粒体膨胀情况：Westernblot检测线粒体细胞色素C（cytochrome C,CytoC）释放;利用荧光探针JC-1在激光共聚集显微镜下观察线粒体膜电位的变化。50、100、200μmol／L Ro5-4864均显著抑制Ca^2＋诱发的520nm处线粒体吸光度的下降,而且抑制Ca^2＋引起的线粒体CytoC释放和线粒体膜电位下降,但ATR可阻断R05—4864的上述作用。结果提示,PBR激动剂可抑制大鼠心肌MPT,保持线粒体CytoC含量和稳定线粒体膜电位,减轻线粒体损伤。PBR的激活可能成为减轻心肌细胞应激性损伤及心肌保护的新方法。     

中枢去甲肾上腺素和内阿片肽系统对苯二氮受体反相激动剂DMCM致焦虑作用的影响

在大鼠条件反射性惊恐反应致焦虑模型上,中枢苯二氮(艹卓)(BZD)受体激动剂安定,可使冲突惊恐反应期(PP)的操作数目显著增加,BZD受体反相激动剂DMCM则显著减少PP的操作数目;DMCM的这一作用,可分别为中枢BZD受体拮抗剂Ro 15-1788,GABA A型受体激动剂蝇蕈醇、阿片受体拮抗剂环丙甲羟二氢吗啡酮和中枢去甲肾上腺素能(NA)突触前α_2受体激动剂可乐定所阻断。结果表明,中枢阿片肽和NA系统共同参与BZD受体反相激动剂DMCM的致焦虑作用。     

GABAA受体的神经药理学研究进展

配体闸门离子通道超家族成员之一的GABAA受体,是一种介导抗焦虑药物、镇静药物、抗惊厥药物、肌肉驰缓药物和失忆活动的多功能药物作用靶标。本文综述了近年来国外有关GABAA受体的神经药理学研究进展。     

中枢ACTH受体研究进展

除垂体以外,中枢神经系统也含有促肾上腺皮质激素（ＡＣＴＨ）能神经元,其神经纤维在中枢具有较广泛的投射。ＡＣＴＨ相关肽类在中枢发挥着多种生理功能。近年来对于中枢ＡＣＴＨ受体的研究取得很大的进展,现已确认ＡＣＴＨ结合位点在中枢具有广泛的分布。新近克隆出的四种ＡＣＴＨ受体中,有两种是中枢神经系统占优势的受体亚型。     

Early ontogeny of the central benzodiazepine receptor in human embryos and fetuses

The early ontogeny of the central benzodiazepine receptor (BZR) was investigated in human embryos and fetuses between 7 and 26 weeks of gestation. Brain tissue was gained from terminated pregnancies or spontaneous abortions. Binding studies, which were performed with 3H-flunitrazepam (FNZ), revealed that specific benzodiazepine binding is already detectable at an embryonal age of 7 weeks post conceptionem. Binding at this early stage can be displaced potently by clonazepam and the inverse agonist beta-CCE. Additionally, 3H-FNZ binding is enhanced by GABA. Thus, benzodiazepine binding is of the central type. Receptor density increases steeply in whole brain between weeks 8 and 11 of gestation. In frontal cortex receptor density increases gradually between weeks 12 and 26 of gestation. No specific fetal disease entity (including trisomy 21) was consistently associated with exceptionally high or low Bmax-values.     

Solubilization of the central benzodiazepine receptor and study of its interaction with nicotinamide

It was shown that nicotinamide and NAD inhibit the specific binding of [3H]flunitrazepam to benzdiazepine receptors without causing a direct influence of gamma-aminobutyric acid (GABA) receptors. The GABA-benzdiazepine complex was separated by solubilization with 0.5% lubrol PX. The solubilized preparations contain the binding sites for [3H]flunitrazepam alone (Kd = 5.9 nm). The Kd value for the membrane-bound benzdiazepine receptor is 2.9 nM. NAD inhibited the specific binding of [3H]flunitrazepam to the solubilized membrane preparation when used at concentrations by several orders of magnitude lower than that of nicotinamide. Using gel filtration on Sepharose 6B-CL, the molecular mass of the soluble benzdiazepine receptor protein was determined.     

Effect of picrotoxinin on benzodiazepine receptor binding

The effect of picrotoxinin on [³H]flunitrazepam binding to benzodiazepine receptors was investigated. In mouse forebrain membranes, picrotoxinin inhibited basal, GABA- and pentobarbital-stimulated [³H]flunitrazepam binding; this inhibitory activity was temperature- and chloride ion-dependent. Scatchard analysis of the data indicates that picrotoxinin decreases the number of binding sites without alterating binding affinity. In cerebellar membranes, picrotoxinin did not alter [³H]flunitrazepam receptor binding.     

Uniform regulation of central and peripheral benzodiazepine binding sites by GABA receptor agonists in rats

Central and peripheral benzodiazepine binding sites were studied in vitro after the administration of GABAA and GABAB agonists. Cerebral cortex and kidney homogenates were used in this study. Muscimol (1.5 mg/kg, intraperitoneally) pretreatment significantly increased the affinity of benzodiazepine binding sites not only in the cerebral cortex but also in the kidneys. Similar changes were obtained with (-) and (+) baclofen (5 mg/kg, intraperitoneally), with the only exception that (-) baclofen in addition to changes in the affinity caused a marked decrease in the number of binding sites in both structures studied. The mechanism of action of GABA agonists on peripheral benzodiazepine binding sites is discussed.     

Lack of specificity in cation effects on solubilized benzodiazepine receptor

Receptors for benzodiazepines (BZ) and -carboline-carboxylic acid ethyl ester (-CCE) has been solubilized with decanoly-N-methylglucamide (DMG), a new kind of nonionic detergent. The apparent dissociation constants of diazepam and -CCE for solubilized receptor were similar to those for synaptic membranes. Sucrose density gradient centrifugation of the solubilized receptor protein revealed that the binding profile of [³H]-CCE essentially parallels that of [³H]diazepam and that both sedimentation coefficients were 10.5S. Co²⁺ and Ni²⁺, which increase [³H]diazepam binding and decrease [³H]-CCE binding to synaptic membranes, remarkably increased the binding of both to the solubilized receptor. Mg²⁺ and Ca²⁺, which had no effect on membrane receptor binding, also enhanced [³H]diazepam and [³H]-CCE binding to the solubilized receptor. The increase in binding in the presence of these divalent cations was due to a change in the apparent number of binding sites, with no change in binding affinities. The relative lack of specificity in divalent cation effects on solubilized BZ receptor may be caused by separation or destruction of the cation recognition site or channel of the BZ receptor complex by solubilization of the synaptic membrane with DMG.